Literature DB >> 28993402

Exercise Intolerance in Heart Failure With Preserved Ejection Fraction: Diagnosing and Ranking Its Causes Using Personalized O2 Pathway Analysis.

Nicholas E Houstis1, Aaron S Eisman1, Paul P Pappagianopoulos1, Luke Wooster1, Cole S Bailey1, Peter D Wagner2, Gregory D Lewis3.   

Abstract

BACKGROUND: Heart failure with preserved ejection fraction (HFpEF) is a common syndrome with a pressing shortage of therapies. Exercise intolerance is a cardinal symptom of HFpEF, yet its pathophysiology remains uncertain.
METHODS: We investigated the mechanism of exercise intolerance in 134 patients referred for cardiopulmonary exercise testing: 79 with HFpEF and 55 controls. We performed cardiopulmonary exercise testing with invasive monitoring to measure hemodynamics, blood gases, and gas exchange during exercise. We used these measurements to quantify 6 steps of oxygen transport and utilization (the O2 pathway) in each patient with HFpEF, identifying the defective steps that impair each one's exercise capacity (peak Vo2). We then quantified the functional significance of each O2 pathway defect by calculating the improvement in exercise capacity a patient could expect from correcting the defect.
RESULTS: Peak Vo2 was reduced by 34±2% (mean±SEM, P<0.001) in HFpEF compared with controls of similar age, sex, and body mass index. The vast majority (97%) of patients with HFpEF harbored defects at multiple steps of the O2 pathway, the identity and magnitude of which varied widely. Two of these steps, cardiac output and skeletal muscle O2 diffusion, were impaired relative to controls by an average of 27±3% and 36±2%, respectively (P<0.001 for both). Due to interactions between a given patient's defects, the predicted benefit of correcting any single one was often minor; on average, correcting a patient's cardiac output led to a 7±0.5% predicted improvement in exercise intolerance, whereas correcting a patient's muscle diffusion capacity led to a 27±1% improvement. At the individual level, the impact of any given O2 pathway defect on a patient's exercise capacity was strongly influenced by comorbid defects.
CONCLUSIONS: Systematic analysis of the O2 pathway in HFpEF showed that exercise capacity was undermined by multiple defects, including reductions in cardiac output and skeletal muscle diffusion capacity. An important source of disease heterogeneity stemmed from variation in each patient's personal profile of defects. Personalized O2 pathway analysis could identify patients most likely to benefit from treating a specific defect; however, the system properties of O2 transport favor treating multiple defects at once, as with exercise training.
© 2017 American Heart Association, Inc.

Entities:  

Keywords:  cardiac output; comorbidity; diagnosis; diffusion; microcirculation; systems biology; taxonomy

Mesh:

Year:  2017        PMID: 28993402      PMCID: PMC5760316          DOI: 10.1161/CIRCULATIONAHA.117.029058

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  41 in total

1.  Lung function abnormalities are highly frequent in patients with heart failure and preserved ejection fraction.

Authors:  Rut Andrea; Alejandra López-Giraldo; Carlos Falces; Patricia Sobradillo; Laura Sanchis; Concepción Gistau; Magda Heras; Manel Sabate; Josep Brugada; Alvar Agustí
Journal:  Heart Lung Circ       Date:  2013-09-08       Impact factor: 2.975

2.  A theoretical analysis of factors determining VO2 MAX at sea level and altitude.

Authors:  P D Wagner
Journal:  Respir Physiol       Date:  1996-12

3.  Determinants of exercise intolerance in elderly heart failure patients with preserved ejection fraction.

Authors:  Mark J Haykowsky; Peter H Brubaker; Jerry M John; Kathryn P Stewart; Timothy M Morgan; Dalane W Kitzman
Journal:  J Am Coll Cardiol       Date:  2011-07-12       Impact factor: 24.094

4.  Limited maximal exercise capacity in patients with chronic heart failure: partitioning the contributors.

Authors:  Fabio Esposito; Odile Mathieu-Costello; Ralph Shabetai; Peter D Wagner; Russell S Richardson
Journal:  J Am Coll Cardiol       Date:  2010-05-04       Impact factor: 24.094

5.  Modeling O₂ transport as an integrated system limiting (.)V(O₂MAX).

Authors:  Peter D Wagner
Journal:  Comput Methods Programs Biomed       Date:  2010-05-18       Impact factor: 5.428

6.  Mechanisms of exercise intolerance in heart failure with preserved ejection fraction: the role of abnormal peripheral oxygen extraction.

Authors:  Bishnu P Dhakal; Rajeev Malhotra; Ryan M Murphy; Paul P Pappagianopoulos; Aaron L Baggish; Rory B Weiner; Nicholas E Houstis; Aaron S Eisman; Stacyann S Hough; Gregory D Lewis
Journal:  Circ Heart Fail       Date:  2014-10-24       Impact factor: 8.790

7.  Contributions of Nondiastolic Factors to Exercise Intolerance in Heart Failure With Preserved Ejection Fraction.

Authors:  Wojciech Kosmala; Aleksandra Rojek; Monika Przewlocka-Kosmala; Andrzej Mysiak; Bozena Karolko; Thomas H Marwick
Journal:  J Am Coll Cardiol       Date:  2016-02-16       Impact factor: 24.094

8.  Low-intensity training increases peak arm VO2 by enhancing both convective and diffusive O2 delivery.

Authors:  R Boushel; I Ara; E Gnaiger; J W Helge; J González-Alonso; T Munck-Andersen; H Sondergaard; R Damsgaard; G van Hall; B Saltin; J A L Calbet
Journal:  Acta Physiol (Oxf)       Date:  2014-03-17       Impact factor: 6.311

9.  Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial.

Authors:  Margaret M Redfield; Horng H Chen; Barry A Borlaug; Marc J Semigran; Kerry L Lee; Gregory Lewis; Martin M LeWinter; Jean L Rouleau; David A Bull; Douglas L Mann; Anita Deswal; Lynne W Stevenson; Michael M Givertz; Elizabeth O Ofili; Christopher M O'Connor; G Michael Felker; Steven R Goldsmith; Bradley A Bart; Steven E McNulty; Jenny C Ibarra; Grace Lin; Jae K Oh; Manesh R Patel; Raymond J Kim; Russell P Tracy; Eric J Velazquez; Kevin J Anstrom; Adrian F Hernandez; Alice M Mascette; Eugene Braunwald
Journal:  JAMA       Date:  2013-03-27       Impact factor: 56.272

Review 10.  Exercise intolerance in heart failure with preserved ejection fraction: more than a heart problem.

Authors:  Bharathi Upadhya; Mark J Haykowsky; Joel Eggebeen; Dalane W Kitzman
Journal:  J Geriatr Cardiol       Date:  2015-05       Impact factor: 3.327

View more
  73 in total

1.  Effect of Inorganic Nitrite vs Placebo on Exercise Capacity Among Patients With Heart Failure With Preserved Ejection Fraction: The INDIE-HFpEF Randomized Clinical Trial.

Authors:  Barry A Borlaug; Kevin J Anstrom; Gregory D Lewis; Sanjiv J Shah; James A Levine; Gabe A Koepp; Michael M Givertz; G Michael Felker; Martin M LeWinter; Douglas L Mann; Kenneth B Margulies; Andrew L Smith; W H Wilson Tang; David J Whellan; Horng H Chen; Victor G Davila-Roman; Steven McNulty; Patrice Desvigne-Nickens; Adrian F Hernandez; Eugene Braunwald; Margaret M Redfield
Journal:  JAMA       Date:  2018-11-06       Impact factor: 56.272

2.  Differential Clinical Profiles, Exercise Responses, and Outcomes Associated With Existing HFpEF Definitions.

Authors:  Jennifer E Ho; Emily K Zern; Luke Wooster; Cole S Bailey; Thomas Cunningham; Aaron S Eisman; Kathryn M Hardin; Giovanna A Zampierollo; Petr Jarolim; Paul P Pappagianopoulos; Rajeev Malhotra; Matthew Nayor; Gregory D Lewis
Journal:  Circulation       Date:  2019-05-28       Impact factor: 29.690

3.  Can Oxygen Transport Analysis Tell Us Why People With Heart Failure With Preserved Ejection Fraction Feel So Poorly?

Authors:  Barry A Borlaug
Journal:  Circulation       Date:  2018-01-09       Impact factor: 29.690

4.  Mechanisms of Chronotropic Incompetence in Heart Failure With Preserved Ejection Fraction.

Authors:  Satyam Sarma; Douglas Stoller; Joseph Hendrix; Erin Howden; Justin Lawley; Sheryl Livingston; Beverley Adams-Huet; Courtney Holmes; David S Goldstein; Benjamin D Levine
Journal:  Circ Heart Fail       Date:  2020-03-13       Impact factor: 8.790

Review 5.  Heart Failure With Preserved Ejection Fraction In Perspective.

Authors:  Marc A Pfeffer; Amil M Shah; Barry A Borlaug
Journal:  Circ Res       Date:  2019-05-24       Impact factor: 17.367

Review 6.  Exercise Therapy and Cardiovascular Toxicity in Cancer.

Authors:  Jessica M Scott; Tormod S Nilsen; Dipti Gupta; Lee W Jones
Journal:  Circulation       Date:  2018-03-13       Impact factor: 29.690

Review 7.  Mitochondrial Dysfunction in Heart Failure With Preserved Ejection Fraction.

Authors:  Anupam A Kumar; Daniel P Kelly; Julio A Chirinos
Journal:  Circulation       Date:  2019-03-12       Impact factor: 29.690

Review 8.  Performance and Interpretation of Invasive Hemodynamic Exercise Testing.

Authors:  C Charles Jain; Barry A Borlaug
Journal:  Chest       Date:  2020-05-28       Impact factor: 9.410

9.  Vitamin D Status and Exercise Capacity in Older Patients with Heart Failure with Preserved Ejection Fraction.

Authors:  Ambarish Pandey; Dalane W Kitzman; Denise K Houston; Haiying Chen; M Kyla Shea
Journal:  Am J Med       Date:  2018-08-01       Impact factor: 4.965

10.  IL-1 Blockade in Patients With Heart Failure With Preserved Ejection Fraction.

Authors:  Benjamin W Van Tassell; Cory R Trankle; Justin M Canada; Salvatore Carbone; Leo Buckley; Dinesh Kadariya; Marco G Del Buono; Hayley Billingsley; George Wohlford; Michele Viscusi; Claudia Oddi-Erdle; Nayef A Abouzaki; Dave Dixon; Giuseppe Biondi-Zoccai; Ross Arena; Antonio Abbate
Journal:  Circ Heart Fail       Date:  2018-08       Impact factor: 8.790

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.